Buy Low, Never Sell - 2 Elite Dividend Stocks Built To Last
Successful investing means ignoring hype and sticking to quality-forever holdings. Read more about two dividend stocks that ...
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...
Metsera, Inc.: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...
Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results ...
The Cincinnati Herald16h
Diabetic foot pain: Expert tips on how to cope
Diabetes-related nerve damage is a significant concern, affecting 1 in 10 people worldwide. Learn about its causes, symptoms, and management strategies.